MedPath

Postoperative pain relief and analgesia after laproscopic cholecystectomy: bupivacaine versus nalbuphine ,when instilled through the laprpscopic port

Phase 4
Active, not recruiting
Conditions
Administration, (2) ICD-10 Condition: K800||Calculus of gallbladder with acutecholecystitis,
Registration Number
CTRI/2020/11/028869
Lead Sponsor
Hakeem Abdul Centenary hospitalNew Delhi
Brief Summary

The aim of the study wasto compare the effectiveness of intraperitoneal bupivacaine and intraperitonealnalbuphine for postoperative pain relief after laproscopic cholecystectomy.

Detailed Description

Not available

Recruitment & Eligibility

Status
Closed to Recruitment of Participants
Sex
All
Target Recruitment
80
Inclusion Criteria

Eighty patients ( 40 in each group) with ASA 1,2, aged 18-60 years, undergoing laproscopic cholecystectomy were be included in the study.

Exclusion Criteria
  • Patients with H/o chronic opioid intake Known allergy to local anaesthetics, Obese or pregnant patients were excluded from the study.
  • Patients those who have chronic pain diseases (not related to choleystitis) or have acute cholecystitis before the surgery were also be excluded When the duration of surgery exceeded 2 hrs or if the surgery got converted to open, were also excluded.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
to compare and assess the VAS score at different intervals and to determine the time of first analgesic request.post operative ,2 ,4 ,6 hrs upto 24 hrs
Secondary Outcome Measures
NameTimeMethod
to compare the analgesic request rate ( number of doses of tramadol in 24 hrs), patient satisfaction score , incidence of shoulder pain and time to return to normal activity.uptl 24 hrs

Trial Locations

Locations (1)

Hakeem Abdul Centenary hospital, New Delhi

🇮🇳

South, DELHI, India

Hakeem Abdul Centenary hospital, New Delhi
🇮🇳South, DELHI, India
Dr Kharat Mohd Batt
Principal investigator
9622457554
khairatm@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.